Kelly J W, Cains G D, Rallings M, Gilmore S J
Alfred Hospital, Melbourne.
Australas J Dermatol. 1991;32(2):85-91. doi: 10.1111/j.1440-0960.1991.tb00071.x.
The safety and efficacy of once daily application of mometasone furoate cream 0.1% was determined by comparison with twice daily applications of betamethasone dipropionate cream 0.05% in a single blind, dual centre, randomized study in patients with a variety of steroid-responsive inflammatory dermatoses, the most common of which was psoriasis. Morning plasma cortisol levels revealed little adrenal suppression in either of the two study groups and there was no significant difference between the two groups. Routine laboratory investigations showed no trends in values outside the normal ranges that were of clinical significance. Less skin atrophy was seen in the group treated with mometasone furoate. In comparison to the betamethasone dipropionate treated group, those treated with mometasone furoate exhibited only slight evidence of skin atrophy, and this was not observed before four to twelve weeks of treatment. Eighteen percent of patients using mometasone reported adverse reactions but all were of limited duration and did not persist despite continued application of the drug. Nine percent of patients using betamethasone dipropionate reported adverse effects. Both drugs were found to be highly effective with no significant difference between the two groups at the termination of the treatment period. Of importance is the fact that whilst mometasone furoate is found to be a highly effective treatment for a variety of steroid-responsive dermatoses, this drug has only a limited potential for production of local and systemic side effects. Thus, a high margin of safety can be expected for patients using this drug.
在一项针对多种对类固醇有反应的炎性皮肤病患者的单盲、双中心、随机研究中，通过与每日两次外用0.05%丙酸倍他米松乳膏对比，来确定每日一次外用0.1%糠酸莫米松乳膏的安全性和有效性。这些皮肤病中最常见的是银屑病。早晨血浆皮质醇水平显示，两个研究组中肾上腺抑制作用均不明显，且两组之间无显著差异。常规实验室检查未发现具有临床意义的超出正常范围的数值变化趋势。糠酸莫米松治疗组出现的皮肤萎缩较少。与丙酸倍他米松治疗组相比，糠酸莫米松治疗组仅表现出轻微的皮肤萎缩迹象，且在治疗4至12周之前未观察到这种情况。使用糠酸莫米松的患者中有18%报告了不良反应，但所有不良反应持续时间有限，尽管继续用药也未持续存在。使用丙酸倍他米松的患者中有9%报告了不良反应。在治疗期结束时发现两种药物均非常有效，两组之间无显著差异。重要的是，虽然糠酸莫米松被发现是治疗多种对类固醇有反应的皮肤病的高效药物，但这种药物产生局部和全身副作用的可能性有限。因此，使用这种药物的患者有望获得很高的安全性。
